Clinical Trials Directory

Trials / No Longer Available

No Longer AvailableNCT02570412

Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

Compassionate Use of Aldoxorubicin in Sarcoma Patients Who Have Failed Prior Chemotherapy

Status
No Longer Available
Phase
Study type
Expanded Access
Enrollment
Sponsor
CytRx · Industry
Sex
All
Age
18 Years
Healthy volunteers

Summary

Compassionate use of aldoxorubicin in sarcoma patients who have failed prior chemotherapy.

Detailed description

This is a compassionate use protocol allowing sarcoma patients that have relapsed after prior therapies and are not eligible for other protocols involving the evaluation of aldoxorubicin to receive aldoxorubicin.

Conditions

Interventions

TypeNameDescription
DRUGaldoxorubicinaldoxorubicin administered at 350 mg/m2

Timeline

First posted
2015-10-07
Last updated
2015-10-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02570412. Inclusion in this directory is not an endorsement.

Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy (NCT02570412) · Clinical Trials Directory